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The pandemic potential of coronaviruses (CoV) has now been 
realised with coronavirus disease 19 (COVID-19) caused by 
SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona-
virus 2). This infection began in December 2019 in Wuhan, 
China before spreading across the globe in a matter of weeks. 
At the time of this submission, there were more than 1.8 mil-
lion cases and 119,000 deaths worldwide [1]. The global health 
community is working furiously to gain a better understanding 
of COVID-19 disease mechanisms and to develop effective 
preventative and treatment strategies. Elderly individuals and 
those with comorbidities, especially cardiovascular, are at an 
increased risk of infection and poor outcomes. Patients with 
Parkinson’s disease (PD) often fall into this high-risk category, 
but may be at even greater risk due to SARS-CoV-2 neuronal 
tropism. We here highlight evidence to support this claim, and 
propose the study of two widely used PD medications for the 
treatment of COVID-19.
Much of our knowledge regarding SARS-CoV-2 comes 
from previous studies of other human coronaviruses (SARS-
-CoV and MERS-CoV), which have caused much smaller 
epidemics. 
Information is now emerging about SARS-CoV-2 charac-
teristics including the risk of acute respiratory distress syn-
drome (ARDS). Current evidence suggests that ARDS results 
from direct lung invasion through the angiotensin-converting 
enzyme 2 (ACE2) receptor, which is expressed on lung alveolar 
cells [2]. A study of rodents identified widespread neuronal 
ACE2 expression in brainstem cardiorespiratory neurons, 
motor cortex, the raphe nucleus, and others [3]. While ACE2’s 
role in the brain is incompletely understood, this diverse CNS 
expression pattern may provide SARS-CoV-2, and other CoVs, 
with a ‘port of entry’ into the CNS.
There are reports of neurological symptoms in patients 
with COVID-19. These are mostly presented as sequelae 
secondary to ARDS, e.g. hypoxic encephalopathy in 20% 
of patients [4]. However, there may be a direct relationship 
between ARDS and the nervous system. Neuroinvasion has 
been documented for many CoVs, including SARS-CoV, 
MERS-CoV, human CoV-OC43 (HCoV-OC43), HCoV-229E, 
mouse hepatitis virus (MHV), and porcine hemagglutinating 
encephalomyelitis coronavirus (HEV) [5]. Rodent models have 
shown that SARS-CoV and MERS-CoV can enter the brain 
after intranasal administration [5]. HEV67, which shares 91% 
homology with HCoV-OC43, gains access to the CNS via 
trans-synaptic transfer from peripheral nerve terminals [5]. 
The avian influenza virus also spreads in this manner, and has 
been traced from the vagus nerve to the solitary nucleus and 
nucleus ambiguus in canines [6]. Involvement of these cardio-
respiratory centres may result in a CNS-mediated component 
of COVID-19 cardiorespiratory manifestations.
The latest evidence indicates that COVID-19 symptoms are 
most severe in elderly individuals with various comorbidities 
such as hypertension, cardiovascular disease, diabetes melli-
tus, and renal disease [4]. This is especially concerning from 
a neurologist’s perspective because age is the strongest risk 
factor for a variety of neurodegenerative diseases, including PD. 
Moreover, comorbid conditions accumulate with increasing 
age. It is unclear whether PD confers direct vulnerability to 
SARS-CoV-2, but parkinsonism is a well-known consequence 
of several viral encephalitides. In 1985, Fishman et al. reported 
that MHV-A59 has a selective affinity for the basal ganglia [7]. 
A subsequent study found enhanced antibody responses to dif-
ferent CoV forms in the cerebrospinal fluid of PD patients [8].
These findings warrant further investigation into SARS-
-CoV-2 vulnerability in PD.
Adamantane derivatives represent a class of medications 
that block NMDA receptor activity, and are effective at decre-
asing excess neuronal activity that may lead to excitotoxicity 
and unwanted neurological symptoms. Amantadine belongs 
to this class. It is an effective treatment for patients with PD 
who have levodopa-induced motor complications. Memantine 
is also an adamantane derivative most often used to slow the 
rate of cognitive decline in patients with dementia, including 
those with PD.
Some adamantane derivates are effective antiviral agents. 
Amantadine was initially marketed as a treatment against in-
fluenza A. By blocking the matrix-2 (M2) protein ion channel, 
amantadine inhibits viral uncoating within host cell endosomes 
[9]. Bananin is an adamantane derivative that acts against the 
SARS coronavirus by blocking the enzyme helicase, which is 
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critical for viral nucleic acid replication [9]. Memantine may in-
hibit ion channel activity of the HCoV-OC43 protein E, similar 
to amantadine’s action on M2 protein, or inhibit viral helicase 
activity like bananin [9]. It is unknown whether amantadine or 
memantine are effective antiviral treatments of SARS-CoV-2.
There is a growing amount of data supporting the treat-
ment of COVID-19 with repurposed non-antiviral agents, 
such as chloroquine, hydroxychloroquine, and azithromycin 
[10, 11]. It is vital to consider possible serious side effects (e.g. QT 
interval prolongation) when administering these medications, 
especially in older patients with cardiac comorbidities [12].
We should consider repurposing other medications, 
especially those with known antiviral properties such as aman-
tadine and memantine. These medications are inexpensive, 
widely used, and have well-known side effect profiles that are 
relatively mild compared to other potential COVID-19 tre-
atments such as hydroxychloroquine. Their ability to cross 
the blood/brain barrier also provides direct CNS access for 
potential neuroprotection. In this manner, amantadine and 
memantine may have a role to play in the prevention and/or 
acute treatment of COVID-19. 
Elderly individuals are at increased risk for a more severe 
disease course and worse outcomes [4]. Levodopa-induced 
motor complications and dementia tend to be later manife-
stations of PD. Consequently, amantadine and memantine are 
typically prescribed to older, more at-risk, patients. Therefore, 
these individuals are ideal candidates for retrospective studies 
to determine whether amantadine and/or memantine can 
reduce one’s risk of infection with COVID-19 or diminish 
symptom severity. Patients receiving amantadine and/or 
memantine may experience QT interval prolongation. We 
recommend careful ECG assessment at treatment onset and 
serial monitoring for individuals receiving one or more of 
these medications, especially if combined with chloroquine.
The COVID-19 pandemic has overwhelmed the healthcare 
systems of many countries. At this time, our most effective 
weapon to prevent healthcare system overload in further 
countries is a combination of social distancing and thorough 
hand hygiene. Sporting events have been cancelled, schools 
have converted to computer-based formats, and countless in-
dividuals must stay at home rather than go to work, sometimes 
even without pay. Each day of increasing viral spread brings 
a greater burden to our economy and way of life. 
We must explore all feasible options for preventing and 
treating COVID-19. Trial repurposing of medications that 
are inexpensive, and readily available, is a low risk and cost-
-effective approach. We propose amantadine and memantine 
as two potential candidates. 
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Glossary
ACE2 — Angiotensin-converting enzyme 2
ARDS — Acute respiratory distress syndrome
CoV — Coronavirus
COVID-19 — coronavirus 19
ECG — electrocardiography
HEV — hemagglutinating encephalomyelitis coronavirus
M2 — Matrix-2
MHV — mouse hepatitis virus
PD — Parkinson’s disease 
SARS-CoV-2 — Severe Acute Respiratory Syndrome Coro-
navirus 2
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